HBM Holdings Surges Nearly 15% as China Approves Clinical Trial Application for Late-Stage Solid Tumor Therapy

Stock News

Aug 20

Shares of HBM Holdings-B (02142) climbed nearly 15% in Hong Kong trading on Monday, with the stock last up 11.73% at HK$16.19, on turnover of HK$278 million.

The surge follows the company's announcement that China's National Medical Products Administration has approved its clinical trial application for HBM7004, a therapy targeting advanced solid tumors. This marks another significant milestone after the company received IND clearance from the U.S. Food and Drug Administration on May 8, 2026.

HBM7004 is a novel B7H4xCD3 bispecific antibody developed on the company's proprietary HBICE® platform, offering a differentiated approach to cancer immunotherapy through both efficacy and safety enhancements. The advancement of HBM7004 further underscores the platform's flexibility and plug-and-play advantages.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1129435717"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1129435717\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1129435717?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-20 15:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1129435717","market":"nz","top_or_hot":-1,"title":"HBM Holdings Surges Nearly 15% as China Approves Clinical Trial Application for Late-Stage Solid Tumor Therapy","media":"Stock News","content":"<p>Shares of <b>HBM Holdings-B</b> (<b>02142</b>) climbed nearly 15% in Hong Kong trading on Monday, with the stock last up 11.73% at HK$16.19, on turnover of HK$278 million.<br><br>The surge follows the company's announcement that China's National Medical Products Administration has approved its clinical trial application for HBM7004, a therapy targeting advanced solid tumors. This marks another significant milestone after the company received IND clearance from the U.S. Food and Drug Administration on May 8, 2026.<br><br>HBM7004 is a novel B7H4xCD3 bispecific antibody developed on the company's proprietary HBICE® platform, offering a differentiated approach to cancer immunotherapy through both efficacy and safety enhancements. The advancement of HBM7004 further underscores the platform's flexibility and plug-and-play advantages.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HBM Holdings Surges Nearly 15% as China Approves Clinical Trial Application for Late-Stage Solid Tumor Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHBM Holdings Surges Nearly 15% as China Approves Clinical Trial Application for Late-Stage Solid Tumor Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-20 15:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>HBM Holdings-B</b> (<b>02142</b>) climbed nearly 15% in Hong Kong trading on Monday, with the stock last up 11.73% at HK$16.19, on turnover of HK$278 million.<br><br>The surge follows the company's announcement that China's National Medical Products Administration has approved its clinical trial application for HBM7004, a therapy targeting advanced solid tumors. This marks another significant milestone after the company received IND clearance from the U.S. Food and Drug Administration on May 8, 2026.<br><br>HBM7004 is a novel B7H4xCD3 bispecific antibody developed on the company's proprietary HBICE® platform, offering a differentiated approach to cancer immunotherapy through both efficacy and safety enhancements. The advancement of HBM7004 further underscores the platform's flexibility and plug-and-play advantages.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"","article_id":"1129435717","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1129435717","pubTimestamp":1787210052,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shares of HBM Holdings-B (02142) climbed nearly 15% in Hong Kong trading on Monday, with the stock last up 11.73% at HK$16.19, on turnover of HK$278 million.The surge follows the company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK1161":"生物科技","BK1574":"生物医药B类股","VXUS":"国际股票ETF-Vanguard","KCAI":"KraneShares China Alpha Index ETF","BK1583":"高瓴概念","BK4588":"碎股","02142":"和铂医药-B"},"translate_title":"中国批准晚期实体瘤治疗临床试验申请，HBM控股飙升近15%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02142":1,"KCAI":1,"VXUS":1},"content_text":"Shares of HBM Holdings-B (02142) climbed nearly 15% in Hong Kong trading on Monday, with the stock last up 11.73% at HK$16.19, on turnover of HK$278 million.The surge follows the company's announcement that China's National Medical Products Administration has approved its clinical trial application for HBM7004, a therapy targeting advanced solid tumors. This marks another significant milestone after the company received IND clearance from the U.S. Food and Drug Administration on May 8, 2026.HBM7004 is a novel B7H4xCD3 bispecific antibody developed on the company's proprietary HBICE® platform, offering a differentiated approach to cancer immunotherapy through both efficacy and safety enhancements. The advancement of HBM7004 further underscores the platform's flexibility and plug-and-play advantages.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}